may be efficacious in p16-addicted cancers.It has been noted early on that p16 expression is confined to those tumors that contain pRB mutations, and a number of non HPV-associated cancer types, including some breast, prostate, lung and high-grade serous ovarian carcinomas express p16.It will be important to determine whether some of these tumors are similarly addicted to p16 expression and whether they are vulnerable to inhibition of KDM6B and/or other epigenetic enzymes that are necessary for p16 expression.
No takes yet. Share an insight, caveat, or question.
Münger et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: